enVVeno Medical Corporation (NASDAQ:NVNO – Get Free Report) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totaling 14,788 shares, a drop of 78.9% from the May 31st total of 70,022 shares. Currently, 2.6% of the company’s stock are short sold. Based on an average trading volume of 7,743 shares, the days-to-cover ratio is presently 1.9 days.
Analysts Set New Price Targets
Separately, Weiss Ratings upgraded shares of enVVeno Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.
Get Our Latest Stock Analysis on NVNO
Institutional Trading of enVVeno Medical
enVVeno Medical Price Performance
Shares of NVNO traded down $0.21 during mid-day trading on Friday, reaching $10.84. The company’s stock had a trading volume of 9,898 shares, compared to its average volume of 7,593. enVVeno Medical has a 12-month low of $8.67 and a 12-month high of $196.70. The company’s 50 day moving average is $10.77 and its 200 day moving average is $10.98. The stock has a market cap of $7.26 million, a PE ratio of -0.42 and a beta of 1.10.
enVVeno Medical (NASDAQ:NVNO – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($5.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.40) by $2.51.
About enVVeno Medical
enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.
The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.
Featured Articles
- Five stocks we like better than enVVeno Medical
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
- MarketBeat Week in Review – 06/22 – 06/26
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.
